<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091870</url>
  </required_header>
  <id_info>
    <org_study_id>SIPCEVA</org_study_id>
    <secondary_id>09453</secondary_id>
    <nct_id>NCT01091870</nct_id>
  </id_info>
  <brief_title>Sildenafil for Prevention of Cerebral Vasospasm</brief_title>
  <acronym>SIPCEVA</acronym>
  <official_title>Sildenafil for Prevention of Cerebral Vasospasm Secondary to Subarachnoid Haemorrhage - Phase II Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Clinical Trial with security and dose testing of Sildenafil Citrate in patients
      with subarachnoid hemorrhage due to a rupture of a cerebral aneurism for prevention of
      cerebral vasospasm. The cerebral vasospasm is a decrease in blood flow that occurs when the
      intracranial vessels lose their capability of self-control of dilations and contractions.
      Patients with subarachnoid hemorrhage without neurological deficits who underwent
      endovascular or surgical correction of the aneurysm can participate in this trial. They will
      be randomized to a daily doses of 75 mg of Sildenafil, 150 mg of Sildenafil or Placebo from
      the third to the 14th day post bleeding. Today there is no proven clinical treatment for
      prevention of cerebral vasospasm.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Absence of inclusion criteria
  </why_stopped>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>New neurological Deficit</measure>
    <time_frame>From third to 14th day post subarachnoid hemorrhage</time_frame>
    <description>Development of clinical symptoms suggestive of vasospasm, which are: afasia, hemiparesis, disorientation, or worsening of consciousness without hydrocephalus or expanding cloth. To access level of consciousness we will use the Glasgow Coma Scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transcranial Ecodoppler</measure>
    <time_frame>From the third to the 14th day after subarachnoid hemorrhage</time_frame>
    <description>Signs of vasospasm in in transcranial ecodoppler.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From the third to the 14th day before subarachnoid hemorrhage.</time_frame>
    <description>General mortality (for any causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>From the third to the 14th day after subarachnoid hemorrhage.</time_frame>
    <description>Drug side effect: hypotension, visual blurring, nasal congestion, angina pectoris, asthma crisis, AV block, digestive bleeding, and priapism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>From the third day after subarachnoid hemorrhage to discharge.</time_frame>
    <description>Time to discharge (period of hospital stay).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rankin Scale</measure>
    <time_frame>At discharge from the hospital.</time_frame>
    <description>Modified Rankin scale at discharge.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Cerebral Vasospasm</condition>
  <condition>Rupture of Intracranial Aneurysm</condition>
  <arm_group>
    <arm_group_label>Placebo: soluble blue pigment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soluble blue pigment for placebo controlling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil, 75mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil citrate, 75 mg daily divided in 3 doses. From third to 14th day after subarachnoid hemorrhage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil, 150 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil citrate, 150 mg daily divided in 3 doses from third to 14th day after subarachnoid hemorrhage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.</description>
    <arm_group_label>Placebo: soluble blue pigment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate, 25 mg, 3 times a day.</intervention_name>
    <description>Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.</description>
    <arm_group_label>Sildenafil, 75mg daily</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate 50 mg, 3 times a day</intervention_name>
    <description>Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.</description>
    <arm_group_label>Sildenafil, 150 mg daily</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 20 and 80 years old

          -  Subarachnoid hemorrhage confirmed by CT with Fisher III or IV criteria (blood in
             cisterns larger than 1 mm with or without blood in the ventricular system).

          -  Aneurysm detected in the conventional angiography, or angio-CT or angio - MRI.

          -  Patient underwent surgery for clipping or endovascular treatment in the first 72 hours
             after the ictus.

          -  Consent form signed by the patient or legal responsible.

        Exclusion Criteria:

          -  Patient (or legal responsible) refuses to participate.

          -  Impossibility to collect consent form.

          -  Hemodynamical instability.

          -  Previous cardiac ischemic disease.

          -  History of cardiac arrhythmia within the last 6 months.

          -  History of Retinitis Pigmentosa.

          -  Previous use of drugs witch can interact with sildenafil (specially nitrates).

          -  Pregnancy.

          -  Known hypersensibility to Sildenafil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Cerutti Franciscatto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Antônio Stefani, DR</last_name>
    <role>Study Director</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ápio Martins Antunes, DR</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thiago Torres de Ávila, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mateus Lasta Beck, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mateus Franzói, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atahualpa Caue Strapasson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sílvia Brustolin, DR</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabiane Backes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.hcpa.ufrgs.br</url>
    <description>Official Site of Hospital de Clínicas de Porto Alegre</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aneurysm</keyword>
  <keyword>Vasospasm</keyword>
  <keyword>sildenafil</keyword>
  <keyword>Viagra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

